Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform.

Delaby C, Muñoz L, Torres S, Nadal A, Le Bastard N, Lehmann S, Lleó A, Alcolea D.

Clin Chim Acta. 2019 Mar;490:98-101. doi: 10.1016/j.cca.2018.12.021. Epub 2018 Dec 20.

PMID:
30579960
2.

Hepcidin: immunoanalytic characteristics.

Wolff F, de Verneuil H, Rucheton B, Lefebvre T, Vialaret J, Ropert-Bouchet M, Cunat S, Aguilar-Martinez P, Lehmann S, Delaby C.

Ann Biol Clin (Paris). 2018 Dec 1;76(6):705-715. doi: 10.1684/abc.2018.1382.

PMID:
30257815
3.

Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.

Fortea J, Carmona-Iragui M, Benejam B, Fernández S, Videla L, Barroeta I, Alcolea D, Pegueroles J, Muñoz L, Belbin O, de Leon MJ, Maceski AM, Hirtz C, Clarimón J, Videla S, Delaby C, Lehmann S, Blesa R, Lleó A.

Lancet Neurol. 2018 Oct;17(10):860-869. doi: 10.1016/S1474-4422(18)30285-0. Epub 2018 Aug 29.

PMID:
30172624
4.

Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale.

Lehmann S, Delaby C, Boursier G, Catteau C, Ginestet N, Tiers L, Maceski A, Navucet S, Paquet C, Dumurgier J, Vanmechelen E, Vanderstichele H, Gabelle A.

Front Aging Neurosci. 2018 May 28;10:138. doi: 10.3389/fnagi.2018.00138. eCollection 2018.

5.

Nano-flow vs standard-flow: Which is the more suitable LC/MS method for quantifying hepcidin-25 in human serum in routine clinical settings?

Vialaret J, Picas A, Delaby C, Bros P, Lehmann S, Hirtz C.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jun 1;1086:110-117. doi: 10.1016/j.jchromb.2018.04.003. Epub 2018 Apr 10.

PMID:
29660664
6.

Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver.

Schmitt C, Lenglet H, Yu A, Delaby C, Benecke A, Lefebvre T, Letteron P, Paradis V, Wahlin S, Sandberg S, Harper P, Sardh E, Sandvik AK, Hov JR, Aarsand AK, Chiche L, Bazille C, Scoazec JY, To-Figueras J, Carrascal M, Abian J, Mirmiran A, Karim Z, Deybach JC, Puy H, Peoc'h K, Manceau H, Gouya L.

J Intern Med. 2018 Jul;284(1):78-91. doi: 10.1111/joim.12750. Epub 2018 Mar 26.

PMID:
29498764
7.

Association between serum hepcidin level and restless legs syndrome.

Dauvilliers Y, Chenini S, Vialaret J, Delaby C, Guiraud L, Gabelle A, Lopez R, Hirtz C, Jaussent I, Lehmann S.

Mov Disord. 2018 Apr;33(4):618-627. doi: 10.1002/mds.27287. Epub 2018 Feb 8.

PMID:
29418021
8.

Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers.

Vercruysse O, Paquet C, Gabelle A, Delbeuck X, Blanc F, Wallon D, Dumurgier J, Magnin E, Martinaud O, Jung B, Bousiges O, Lehmann S, Delaby C, Quillard-Murain M, Peoc H K, Laplanche JL, Bouaziz-Amar E, Hannequin D, Sablonniere B, Buee L, Hugon J, Schraen S, Pasquier F, Bombois S, For The E-Plm Group.

Curr Alzheimer Res. 2018;15(7):691-700. doi: 10.2174/1567205015666180110113238.

PMID:
29318973
9.

Impact of iron deficiency diagnosis using hepcidin mass spectrometry dosage methods on hospital stay and costs after a prolonged ICU stay: Study protocol for a multicentre, randomised, single-blinded medico-economic trial.

Lasocki S, Puy H, Mercier G, Lehmann S; Hepcidane study group.

Anaesth Crit Care Pain Med. 2017 Dec;36(6):391-396. doi: 10.1016/j.accpm.2017.04.009. Epub 2017 Sep 14.

PMID:
28919067
10.

Hemolytic anemia repressed hepcidin level without hepatocyte iron overload: lesson from Günther disease model.

Millot S, Delaby C, Moulouel B, Lefebvre T, Pilard N, Ducrot N, Ged C, Lettéron P, de Franceschi L, Deybach JC, Beaumont C, Gouya L, De Verneuil H, Lyoumi S, Puy H, Karim Z.

Haematologica. 2017 Feb;102(2):260-270. doi: 10.3324/haematol.2016.151621. Epub 2016 Nov 10.

11.

Added value of hepcidin quantification for the diagnosis and follow-up of anemia-related diseases.

Lefebvre T, Lasocki S, Fénéant-Thibault M, Lamy PJ, Cunat S, Ropert-Bouchet M, Aguilar-Martinez P, Lehmann S, Delaby C.

Ann Biol Clin (Paris). 2017 Feb 1;75(1):9-18. doi: 10.1684/abc.2016.1208. Review.

PMID:
28132948
12.

Looking for new biomarkers of skin wound vitality with a cytokine-based multiplex assay: preliminary study.

Peyron PA, Baccino É, Nagot N, Lehmann S, Delaby C.

Ann Biol Clin (Paris). 2017 Feb 1;75(1):53-60. doi: 10.1684/abc.2016.1214.

PMID:
28132942
13.

Quantification of hepcidin-25 in human cerebrospinal fluid using LC-MS/MS.

Delaby C, Bros P, Vialaret J, Moulinier A, Delatour V, Gabelle A, Lehmann S, Hirtz C.

Bioanalysis. 2017 Feb;9(4):337-347. doi: 10.4155/bio-2016-0240. Epub 2017 Jan 20.

PMID:
28106476
14.

Development of new quantitative mass spectrometry and semi-automatic isofocusing methods for the determination of Apolipoprotein E typing.

Hirtz C, Vialaret J, Nouadje G, Schraen S, Benlian P, Mary S, Philibert P, Tiers L, Bros P, Delaby C, Gabelle A, Lehmann S.

Clin Chim Acta. 2016 Feb 15;454:33-8. doi: 10.1016/j.cca.2015.12.020. Epub 2015 Dec 19.

PMID:
26707914
15.

Central Nervous System and Peripheral Inflammatory Processes in Alzheimer's Disease: Biomarker Profiling Approach.

Delaby C, Gabelle A, Blum D, Schraen-Maschke S, Moulinier A, Boulanghien J, Séverac D, Buée L, Rème T, Lehmann S.

Front Neurol. 2015 Aug 24;6:181. doi: 10.3389/fneur.2015.00181. eCollection 2015.

16.

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study.

Dumurgier J, Schraen S, Gabelle A, Vercruysse O, Bombois S, Laplanche JL, Peoc'h K, Sablonnière B, Kastanenka KV, Delaby C, Pasquier F, Touchon J, Hugon J, Paquet C, Lehmann S.

Alzheimers Res Ther. 2015 Jun 1;7(1):30. doi: 10.1186/s13195-015-0114-5. eCollection 2015.

17.

Analytical challenges related to the use of biomarker ratios for the biological diagnosis of Alzheimer's disease.

Lehmann S, Delaby C, Paquet C, Gabelle A.

Clin Chem Lab Med. 2015 Jul;53(8):e175-7. doi: 10.1515/cclm-2014-1232. No abstract available.

PMID:
25870963
18.

A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles.

Lehmann S, Dumurgier J, Schraen S, Wallon D, Blanc F, Magnin E, Bombois S, Bousiges O, Campion D, Cretin B, Delaby C, Hannequin D, Jung B, Hugon J, Laplanche JL, Miguet-Alfonsi C, Peoc'h K, Philippi N, Quillard-Muraine M, Sablonnière B, Touchon J, Vercruysse O, Paquet C, Pasquier F, Gabelle A.

Alzheimers Res Ther. 2014 Jun 26;6(3):38. doi: 10.1186/alzrt267. eCollection 2014.

19.

Systemic delivery of siRNA down regulates brain prion protein and ameliorates neuropathology in prion disorder.

Lehmann S, Relano-Gines A, Resina S, Brillaud E, Casanova D, Vincent C, Hamela C, Poupeau S, Laffont M, Gabelle A, Delaby C, Belondrade M, Arnaud JD, Alvarez MT, Maurel JC, Maurel P, Crozet C.

PLoS One. 2014 Feb 14;9(2):e88797. doi: 10.1371/journal.pone.0088797. eCollection 2014.

20.

Impact of harmonization of collection tubes on Alzheimer's disease diagnosis.

Lehmann S, Schraen S, Quadrio I, Paquet C, Bombois S, Delaby C, Dorey A, Dumurgier J, Hirtz C, Krolak-Salmon P, Laplanche JL, Moreaud O, Peoc'h K, Rouaud O, Sablonnière B, Thouvenot E, Touchon J, Vercruysse O, Hugon J, Gabelle A, Pasquier F, Perret-Liaudet A.

Alzheimers Dement. 2014 Oct;10(5 Suppl):S390-S394.e2. doi: 10.1016/j.jalz.2013.06.008. Epub 2013 Oct 23.

PMID:
24269268

Supplemental Content

Loading ...
Support Center